These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28916511)

  • 1. Failure to Treat Life-Threatening Ventricular Tachyarrhythmias in Contemporary Implantable Cardioverter-Defibrillators: Implications for Strategic Programming.
    Thøgersen AM; Larsen JM; Johansen JB; Abedin M; Swerdlow CD
    Circ Arrhythm Electrophysiol; 2017 Sep; 10(9):e005305. PubMed ID: 28916511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks.
    Silver MT; Sterns LD; Piccini JP; Joung B; Ching CK; Pickett RA; Rabinovich R; Liu S; Peterson BJ; Lexcen DR;
    Heart Rhythm; 2015 Mar; 12(3):545-553. PubMed ID: 25460168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.
    Stiles MK; Fauchier L; Morillo CA; Wilkoff BL;
    Europace; 2019 Sep; 21(9):1442-1443. PubMed ID: 31090914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventricular arrhythmia detection for contemporary Biotronik and Abbott implantable cardioverter defibrillators with markedly prolonged detection in Biotronik devices.
    Oesterle A; Dhruva SS; Pellegrini CN; Liem B; Raitt MH
    J Interv Card Electrophysiol; 2023 Oct; 66(7):1679-1691. PubMed ID: 36737506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.
    Stiles MK; Fauchier L; Morillo CA; Wilkoff BL
    J Interv Card Electrophysiol; 2020 Oct; 59(1):135-144. PubMed ID: 31960345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.
    Stiles MK; Fauchier L; Morillo CA; Wilkoff BL
    Heart Rhythm; 2020 Jan; 17(1):e220-e228. PubMed ID: 31103461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality: The ADVANCE III Trial.
    Gasparini M; Lunati MG; Proclemer A; Arenal A; Kloppe A; Martínez Ferrer JB; Hersi AS; Gulaj M; Wijffels MCE; Santi E; Manotta L; Varma N
    JACC Clin Electrophysiol; 2017 Nov; 3(11):1275-1282. PubMed ID: 29759624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
    JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable Cardioverter Defibrillator Programming Characteristics, Shocked Rhythms, and Survival Among Patients Under Thirty Years of Age.
    Chang PM; Powell BD; Jones PW; Carter N; Hayes DL; Saxon LA
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1183-1190. PubMed ID: 27334356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
    Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
    J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device.
    Richardson TD; Hale L; Arteaga C; Xu M; Keebler M; Schlendorf K; Danter M; Shah A; Lindenfeld J; Ellis CR
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients.
    Fischer A; Ousdigian KT; Johnson JW; Gillberg JM; Wilkoff BL
    Heart Rhythm; 2012 Jan; 9(1):24-31. PubMed ID: 21835150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 20. Failure to detect life-threatening arrhythmias in ICDs using single-chamber detection criteria.
    Stroobandt RX; Duytschaever MF; Strisciuglio T; Van Heuverswyn FE; Timmers L; De Pooter J; Knecht S; Vandekerckhove YR; Kucher A; Tavernier RH
    Pacing Clin Electrophysiol; 2019 Jun; 42(6):583-594. PubMed ID: 30657188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.